X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs PLETHICO PHARMA - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA PLETHICO PHARMA ABBOTT INDIA/
PLETHICO PHARMA
 
P/E (TTM) x 44.2 -1.1 - View Chart
P/BV x 11.0 0.0 65,914.4% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ABBOTT INDIA   PLETHICO PHARMA
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-16
PLETHICO PHARMA
Mar-14
ABBOTT INDIA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs6,015395 1,523.2%   
Low Rs3,70731 11,843.5%   
Sales per share (Unadj.) Rs1,236.9604.4 204.6%  
Earnings per share (Unadj.) Rs122.232.5 376.2%  
Cash flow per share (Unadj.) Rs129.051.3 251.3%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs521.2473.6 110.1%  
Shares outstanding (eoy) m21.2534.08 62.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.90.4 1,114.6%   
Avg P/E ratio x39.86.6 606.4%  
P/CF ratio (eoy) x37.74.2 907.8%  
Price / Book Value ratio x9.30.5 2,072.4%  
Dividend payout %28.60-   
Avg Mkt Cap Rs m103,2967,262 1,422.3%   
No. of employees `0003.0NA-   
Total wages/salary Rs m3,3701,596 211.1%   
Avg. sales/employee Rs Th8,891.8NM-  
Avg. wages/employee Rs Th1,140.0NM-  
Avg. net profit/employee Rs Th878.3NM-  
INCOME DATA
Net Sales Rs m26,28420,598 127.6%  
Other income Rs m504386 130.6%   
Total revenues Rs m26,78920,984 127.7%   
Gross profit Rs m3,6652,818 130.1%  
Depreciation Rs m144642 22.5%   
Interest Rs m81,593 0.5%   
Profit before tax Rs m4,017969 414.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,421-138 -1,026.9%   
Profit after tax Rs m2,5961,107 234.6%  
Gross profit margin %13.913.7 101.9%  
Effective tax rate %35.4-14.3 -247.6%   
Net profit margin %9.95.4 183.8%  
BALANCE SHEET DATA
Current assets Rs m14,44618,877 76.5%   
Current liabilities Rs m4,72511,896 39.7%   
Net working cap to sales %37.033.9 109.1%  
Current ratio x3.11.6 192.7%  
Inventory Days Days5136 143.0%  
Debtors Days Days20198 9.9%  
Net fixed assets Rs m1,1139,861 11.3%   
Share capital Rs m213341 62.4%   
"Free" reserves Rs m10,80812,331 87.7%   
Net worth Rs m11,07616,139 68.6%   
Long term debt Rs m04,706 0.0%   
Total assets Rs m16,24133,146 49.0%  
Interest coverage x497.01.6 30,907.7%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x1.60.6 260.4%   
Return on assets %16.08.1 196.9%  
Return on equity %23.46.9 341.8%  
Return on capital %36.312.3 295.7%  
Exports to sales %0.621.4 2.9%   
Imports to sales %12.615.2 83.0%   
Exports (fob) Rs m1624,402 3.7%   
Imports (cif) Rs m3,3223,136 105.9%   
Fx inflow Rs m2684,402 6.1%   
Fx outflow Rs m3,9273,184 123.4%   
Net fx Rs m-3,6591,219 -300.3%   
CASH FLOW
From Operations Rs m2,5142,437 103.2%  
From Investments Rs m-800-6,265 12.8%  
From Financial Activity Rs m-8032,490 -32.2%  
Net Cashflow Rs m912-1,337 -68.2%  

Share Holding

Indian Promoters % 0.0 82.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 4.3 183.7%  
FIIs % 0.1 5.5 1.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.1 7.5 228.0%  
Shareholders   18,270 10,665 171.3%  
Pledged promoter(s) holding % 0.0 85.7 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  UNICHEM LAB  GSK PHARMA  DR. DATSONS LABS  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Feb 23, 2018 01:57 PM

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA - FULFORD INDIA COMPARISON

COMPARE ABBOTT INDIA WITH

MARKET STATS